Dosage reduction may decrease toxicities; however, additional pharmaceutical drugs are often required to counteract the adverse effects of calcineurin inhibitor therapy. (thepsoriasisprogram.com)
For example, CRAC channels in T cells have been clinically validated as important drug targets through human mutations and the use of calcineurin inhibitors that act downstream from CRAC channels. (cnbc.com)
Newer non-steroidal medicines called calcineurin inhibitors are another option. (health.com)